Ask AI

Capsule Summaries

Share

Program Content

Activities

  • MATTERHORN OS
    Phase III MATTERHORN: Final OS and EFS by Pathologic Outcomes With Durvalumab + FLOT vs Placebo + FLOT in Resectable Gastric/GEJ Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 21, 2025

  • DESTINY-Breast05
    DESTINY-Breast05: Interim Analysis of a Phase III Trial of Adjuvant T-DXd vs T-DM1 for High-Risk HER2+ EBC With Residual Invasive Disease After Neoadjuvant Therapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2025

  • FLAURA2 OS Subgroup
    FLAURA2: OS Outcomes by Baseline Prognostic Factors in EGFR-Mutated NSCLC Receiving 1L Osimertinib ± Platinum-Based CT
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 23, 2025

  • TROPION-Breast02
    TROPION-Breast02: Dato-DXd vs Investigator’s Choice of CT as 1L Treatment in Patients With TNBC Who Are Not Candidates for Immunotherapy
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2025

  • ASCENT-03
    ASCENT-03: Phase III Trial of 1L Sacituzumab Govitecan vs Chemotherapy for Patients With Advanced TNBC Ineligible for PD-1/PD-L1 Inhibitors
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2025

  • DESTINY-Breast11
    DESTINY-Breast11: Phase III Study of Neoadjuvant T-DXd With or Without THP vs ddAC-THP in Patients With High-Risk HER2+ EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2025

  • MDT BRIDGE
    MDT-BRIDGE: Phase II Trial of Neoadjuvant Durvalumab + CT and Subsequent Surgery + Adjuvant Durvalumab or CRT + Consolidation Durvalumab for Resectable Stage IIB-IIIB NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2025

  • First-line Zongertinib
    Beamion LUNG-1: Phase I Study of Zongertinib as First-line Treatment for Advanced HER2-Mutant NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 27, 2025

  • HARMONi 6
    HARMONi-6: Ivonescimab + CT vs Tislelizumab + CT as 1L Therapy for Stage IIIB-IV Squamous NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 27, 2025

  • monarchE Primary OS Analysis
    monarchE: Primary Analysis of OS With Adjuvant Abemaciclib Plus ET in Patients With High-Risk, Node-Positive, HR+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 28, 2025

  • ASCENT 04 KEYNOTE D19 PROs
    ASCENT-04/KEYNOTE-D19: Patient-Reported Outcomes of 1L Sacituzumab Govitecan vs CT + Pembrolizumab in PD-L1–Positive Advanced TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 28, 2025

  • DeLLphi-303
    DeLLphi-303: Phase Ib Study of 1L SoC Chemoimmunotherapy + Tarlatamab in Extensive-Stage Small-Cell Lung Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 28, 2025

  • EDGE Gastric Arm A1
    EDGE-Gastric Arm A1 Update: Phase II Trial of Domvanalimab, Zimberelimab, and FOLFOX in Previously Untreated Advanced HER2-Negative GC/GEJC/EAC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 29, 2025

  • KRAS G12D Inhibitor HRS 4642
    Phase I Trial of the KRAS G12D Inhibitor HRS-4642 in Previously Treated Advanced KRAS G12D–Mutant NSCLC and PDAC
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 29, 2025

  • OptiTROP Lung04
    OptiTROP-Lung04: Phase III Trial of Sacituzumab Tirumotecan vs Chemotherapy in EGFRm NSCLC After Progression on EGFR-TKIs
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 29, 2025

  • SOHO-01
    SOHO-01: Phase I/II Study of Sevabertinib in Advanced HER2-Mutant NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 30, 2025

  • VIKTORIA 1 PIK3CA WT
    VIKTORIA-1: Gedatolisib + Fulvestrant ± Palbociclib vs Fulvestrant in HR+/HER2- Advanced Breast Cancer With PIK3CA Wild-Type Status
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 31, 2025

  • evERA BC
    evERA BC: Phase III Trial of Giredestrant + Everolimus in Advanced ER+/HER2- Breast Cancer Previously Treated With a CDK4/6 Inhibitor
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 31, 2025

  • DYNAMIC III ctDNA Negative
    DYNAMIC-III: De-escalation of Adjuvant CT in the Postoperative ctDNA-Negative Cohort of Patients With Stage III Colon Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 31, 2025

  • FORTITUDE-101
    FORTITUDE-101: Bemarituzumab + mFOLFOX6 vs Placebo + mFOLFOX6 in Patients With Advanced/Metastatic FGFR2b  -Overexpressing G/GEJ Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 03, 2025

  • INCB161734
    Phase I Trial of the KRAS G12D Inhibitor INCB161734 in Previously Treated KRAS G12D–Mutant Advanced Solid Tumors
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 03, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly